Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Indium oxine** is a radiopharmaceutical agent composed of a neutral, lipid-soluble complex formed by the coordination of three molecules of 8-hydroxyquinoline (oxine) with the radioactive isotope indium-111. Its primary use is in nuclear medicine for the radiolabeling of leukocytes (white blood cells) to facilitate scintigraphic imaging of sites of inflammation, abscess, or infection. Following intravenous administration, the complex penetrates cell membranes, after which indium-111 dissociates and binds to cytoplasmic components, enabling its retention within the cells. The indium-111 isotope emits gamma rays (171 and 245 keV) that can be detected by gamma cameras, supporting diagnostic imaging. Indium oxine is used especially for localizing inflammatory processes to which leukocytes migrate and is also employed for labeling platelets to detect thrombi. The molecular formula is C27H18InN3O3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indium oxine.